Abstract
Cancer-associated fibroblasts (CAFs) are a recognized cause of tumor resistance to immune checkpoint blockade therapy, but the underlying mechanisms remain elusive. This study establishes a bone marrow-derived CAF (BMF)-rich tumor model to demonstrate that BMF-mixed tumor xenografts are resistant to anti-PD-L1 antibody immunotherapy compared to pure tumor xenografts. In vitro co-culture assays reveal that cancer cells induce BMFs to overexpress PD-L1 via the activation of the Wnt/β-catenin signaling pathway. Pharmacological inhibition of Wnt signaling or genetic knockout of PD-L1 in BMFs restores sensitivity to PD-L1 blockade. Combination therapy significantly potentiates therapeutic outcomes, suggesting that Wnt inhibition is a viable strategy to overcome BMF-mediated immunotherapy resistance.
Introduction
Immune checkpoint blockade (ICB) therapy, specifically targeting the PD-1/PD-L1 axis, has revolutionized oncology. However, fewer than 20% of patients respond effectively due to "immune resistance" driven by the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) play a critical role in this resistance. This paper focuses on a specific subset—bone marrow-derived myofibroblasts (BMFs)—and investigates how they act as an immune shield for tumors, evading anti-PD-L1 therapy.
Methods and Experimental Design
The researchers employed a multi-disciplinary approach combining in vivo mouse models and in vitro cell signaling assays. BMF-rich tumor models were created by injecting mice with a mixture of tumor cells (lung carcinoma or colorectal cancer) and BMFs.
To dissect cellular crosstalk, co-culture systems were established, and transcriptomic changes were analyzed via microarray. Genetic engineering (CRISPR/Cas9) was used to specifically knock out PD-L1 in BMFs, while pharmacological inhibitors (XAV-939 and Wnt-C59) were used to target the Wnt/β-catenin pathway.
Results
BMFs Drive Immunotherapy Resistance
The study confirmed that the presence of BMFs significantly impairs the efficacy of anti-PD-L1 therapy. While pure tumor xenografts responded well to treatment, BMF-mixed tumors showed negligible growth inhibition, confirming that BMFs act as an external immune shield.
The Role of the Wnt/β-catenin Pathway
Mechanistic analysis revealed that tumor cells activate the Wnt/β-catenin signaling pathway in BMFs, leading to a dramatic upregulation of PD-L1 on the fibroblast surface. Interestingly, PD-L1 expression did not increase significantly on the cancer cells themselves in these co-cultures, suggesting that BMFs serve as a primary "immune decoy." Knocking out PD-L1 specifically in BMFs increased the tumor inhibitory rate of anti-PD-L1 therapy from 17.8% to 55.1%.
Synergistic Effects of Wnt Inhibition
Combining the Wnt inhibitor XAV-939 with anti-PD-L1 therapy significantly potentiated the therapeutic outcome. This combination led to a surge in tumor-infiltrating CD8+ T cells (reaching 37%, up from ~23% in monotherapy) and increased IFN-γ production. Importantly, the treatment was well-tolerated, showing no significant toxicity in mouse models.
Conclusion
This research highlights the critical role of stromal PD-L1 in mediating immune resistance. By identifying the Wnt/β-catenin pathway as the driver of BMF-mediated protection, the study provides a clear therapeutic target. Combining Wnt inhibitors with standard ICB therapies offers a promising strategy to improve outcomes for patients with CAF-rich, immunotherapy-resistant tumors.
Summary updated